Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticholinergic agents in asthma and COPD.

Nicholas J Gross1

  • 1Stritch-Loyola School of Medicine, Voluntary Attending Physician, Hines VA Hospital, Chicago, Hines, IL 60141, USA. Nicholas.gross@med.va.gov

European Journal of Pharmacology
|February 21, 2006
PubMed
Summary

Anticholinergic bronchodilators, including ipratropium, oxitropium, and tiotropium, effectively treat obstructive airway diseases like asthma and COPD. These agents are safe, well-tolerated, and offer varying durations of action for disease management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease.

International journal of chronic obstructive pulmonary disease·2018
Same author

Nebulized Long-Acting Beta2-Agonists: More Than Just Bridging Gaps in the Management of Symptomatic COPD.

Chronic obstructive pulmonary diseases (Miami, Fla.)·2017
Same author

New Therapies for Asthma and Chronic Obstructive Pulmonary Disease.

American journal of respiratory and critical care medicine·2016
Same author

Rising Costs of COPD and the Potential for Maintenance Therapy to Slow the Trend.

American health & drug benefits·2014
Same author

The COPD pipeline XXIV.

COPD·2013
Same author

The COPD pipeline XXII.

COPD·2013

Area of Science:

  • Pharmacology
  • Respiratory Medicine

Background:

  • Anticholinergic agents are crucial bronchodilators for managing obstructive airway diseases.
  • Approved inhaled anticholinergics include ipratropium bromide, oxitropium bromide, and tiotropium bromide, derived from atropine.

Purpose of the Study:

  • To review the clinical uses and characteristics of inhaled anticholinergic bronchodilators.
  • To highlight their efficacy and safety in treating asthma and chronic obstructive pulmonary disease (COPD).

Main Methods:

  • Review of approved synthetic quaternary ammonium anticholinergic agents.
  • Discussion of their pharmacokinetic properties, duration of action, and clinical applications.

Main Results:

  • Inhaled anticholinergics are poorly absorbed, ensuring localized action in the airways.

Related Experiment Videos

  • Ipratropium and oxitropium offer short-acting bronchodilation (4-8 hours), suitable for stable disease and exacerbations.
  • Tiotropium provides long-acting bronchodilation (1-2 days), enabling once-daily COPD maintenance therapy.

    • Conclusions:

    • Inhaled anticholinergic agents are safe and well-tolerated with a wide therapeutic margin.
    • These medications are valuable for both asthma and COPD management, with tiotropium offering extended duration for COPD treatment.